Keeping Track: Approvals For Xultophy, Soliqua And Darzalex; NDAs From Intarcia And GSK; Complete Response For Green Cross
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker
You may also be interested in...
Drug Rejection Hearings Are Having A Moment At US FDA
With Intarcia's request, the rarely used mechanism could now produce two hearings this year, but outcomes of the few other times the process has been undertaken should not generate a lot of confidence for sponsors that this a path that they want to go down.
Keeping Track: Scenesse, Reyvow, and Beovu Make Trio Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: A Lilly Breast Cancer Approval, A Couple Of CRLs, And A Plethora Of Priority Reviews
The latest drug development news and highlights from our Performance Tracker.